You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
Aro Biotherapeutics Names Cancer Biologist McMahon and Protein Structure and Design Expert Swanson to its Scientific Advisory Board
Login
Username:

Password:


Related Headlines

PharmaEssentia expands North American footprint with acquisition of Canadian partner FORUS Therapeutics

FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer

Harbour BioMed IND for HBM7004 accepted by China's NMPA

FDA grants rare paediatric disease designation to RedHill's opaganib

GSK to acquire Nuvalent for USD10.6bn to expand lung cancer portfolio

Adcentrx Therapeutics' ADRX-0405 granted Chinese regulatory IND clearance to treat late-stage solid tumours

Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma

OriCell's GPC3 CAR-T Phase II hepatocellular carcinoma trial receives Chinese regulatory clearance

Owkin to build AI agents as part of K Pro collaboration with Sanofi

Arcus Biosciences enters clinical trial collaboration with Bristol Myers Squibb in kidney cancer programme

Lupin and Natco secure US FDA approval for generic Eribulin Mesylate Injection

Evogene completes Phase 1 study of BMC128 in combination with Nivolumab

Cumberland Pharmaceuticals and Vanderbilt Health report data from Phase 2a trial of ifetroban to prevent cancer metastasis

Creatv Bio partners with Neovia Oncology to study multiple drug resistance in solid tumours

FDA accepts Genentech's giredestrant application for early-stage breast cancer

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026